$9.34
0.97% today
Nasdaq, Feb 05, 04:20 pm CET
ISIN
US19240Q2012
Symbol
COGT
Sector
Industry

Cogent Biosciences Inc Stock price

$9.25
+1.19 14.76% 1M
+0.11 1.20% 6M
+1.45 18.59% YTD
+3.55 62.28% 1Y
+2.46 36.23% 3Y
+6.13 196.09% 5Y
-35.19 79.19% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.26 2.89%
ISIN
US19240Q2012
Symbol
COGT
Sector
Industry

Key metrics

Market capitalization $1.02b
Enterprise Value $814.68m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 5.01
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-260.43m
Free Cash Flow (TTM) Free Cash Flow $-192.10m
Cash position $335.52m
EPS (TTM) EPS $-2.48
P/E forward negative
Short interest 9.37%
Show more

Is Cogent Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Cogent Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Cogent Biosciences Inc forecast:

8x Buy
73%
3x Hold
27%

Analyst Opinions

11 Analysts have issued a Cogent Biosciences Inc forecast:

Buy
73%
Hold
27%

Financial data from Cogent Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 4.04 4.04
8% 8%
-
-4.04 -4.04
8% 8%
-
- Selling and Administrative Expenses 37 37
32% 32%
-
- Research and Development Expense 215 215
36% 36%
-
-256 -256
35% 35%
-
- Depreciation and Amortization 4.04 4.04
8% 8%
-
EBIT (Operating Income) EBIT -260 -260
34% 34%
-
Net Profit -242 -242
36% 36%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cogent Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cogent Biosciences Inc Stock News

Positive
Seeking Alpha
14 days ago
Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-cap biotech and biopharma stocks. Today, we look at three of these names that have seen notable recent purchases from insiders and/or beneficial owners.
Positive
Seeking Alpha
18 days ago
Bezuclastinib is COGT's main value driver, currently undergoing 3 late-stage trials for SM and GIST. COGT's SUMMIT Part 2 for nonAdvSM will give us decisive data in July 2025, which I consider its main catalyst this year. Bezuclastinib could target an aggregate TAM of up to $2.5 billion across NonAdvSM, AdvSM, and GIST, which dwarves its current market cap.
Neutral
GlobeNewsWire
about 2 months ago
56% mean improvement in Total Symptom Score (TSS) at 24 weeks with 76% of patients achieving at least a 50% reduction in TSS
More Cogent Biosciences Inc News

Company Profile

Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. The firm’s technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Head office United States
CEO Andrew Robbins
Employees 164
Founded 2014
Website www.cogentbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today